Nicotine absorption from e-cigarettes over 12 months.

Adult Cotinine / metabolism Electronic Nicotine Delivery Systems Female Humans Male Middle Aged Nicotine / administration & dosage Nicotinic Agonists / administration & dosage Saliva / chemistry Smokers Vaping / metabolism
Cotinine E-cigarettes Nicotine absorption Nicotine concentrations Titration Vapers

Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
04 2019
Historique:
received: 27 04 2018
accepted: 20 07 2018
pubmed: 29 7 2018
medline: 17 6 2020
entrez: 29 7 2018
Statut: ppublish

Résumé

Research indicates that, over time, exclusive e-cigarette users (vapers) gradually reduce the nicotine concentration in their e-liquid and transition to more sophisticated devices. Alongside this, consumption of e-liquid increases and constant cotinine levels are maintained. We aimed to confirm these observations in 27 experienced vapers tested at baseline and 12 months later, by measuring nicotine absorption (via salivary levels of the nicotine metabolite cotinine; ng/mL), nicotine concentrations in e-liquid (mg/mL), volume of e-liquid consumed (mL per day), device types and flavours used, both at baseline and 12 months. Vapers reduced both their nicotine concentrations in e-liquid over 12 months (from 13.83 mg/mL at baseline to 9.91 at follow up) but significantly increased their e-liquid consumption (from 4.44 to 6.84 mL). No significant changes in salivary cotinine concentrations (370.88 ng/mL at baseline and 415.78 ng/mL at follow up) were observed. There was an increase in sub-ohming (using an atomiser coil with resistance of <1 Ω with increased power) at 12 months, and in the use of fruit flavoured e-liquids. Our sample of experienced vapers reduced the concentration of nicotine in their e-liquid over time, but maintained their nicotine intake possibly through self-titration via more intensive puffing. Findings suggest there may be little benefit in reducing nicotine e-liquid concentration since this appears to result in higher e-liquid consumption which may incur both a financial and health cost. Gaining an understanding of underlying reasons for lowering e-liquid concentration would be a useful line of empirical enquiry.

Sections du résumé

BACKGROUND
Research indicates that, over time, exclusive e-cigarette users (vapers) gradually reduce the nicotine concentration in their e-liquid and transition to more sophisticated devices. Alongside this, consumption of e-liquid increases and constant cotinine levels are maintained.
AIMS
We aimed to confirm these observations in 27 experienced vapers tested at baseline and 12 months later, by measuring nicotine absorption (via salivary levels of the nicotine metabolite cotinine; ng/mL), nicotine concentrations in e-liquid (mg/mL), volume of e-liquid consumed (mL per day), device types and flavours used, both at baseline and 12 months.
RESULTS
Vapers reduced both their nicotine concentrations in e-liquid over 12 months (from 13.83 mg/mL at baseline to 9.91 at follow up) but significantly increased their e-liquid consumption (from 4.44 to 6.84 mL). No significant changes in salivary cotinine concentrations (370.88 ng/mL at baseline and 415.78 ng/mL at follow up) were observed. There was an increase in sub-ohming (using an atomiser coil with resistance of <1 Ω with increased power) at 12 months, and in the use of fruit flavoured e-liquids.
CONCLUSIONS
Our sample of experienced vapers reduced the concentration of nicotine in their e-liquid over time, but maintained their nicotine intake possibly through self-titration via more intensive puffing. Findings suggest there may be little benefit in reducing nicotine e-liquid concentration since this appears to result in higher e-liquid consumption which may incur both a financial and health cost. Gaining an understanding of underlying reasons for lowering e-liquid concentration would be a useful line of empirical enquiry.

Identifiants

DOI: 10.1016/j.addbeh.2018.07.019 PMID: 30054021
pubmed: 30054021
pii: S0306-4603(18)30806-2
doi: 10.1016/j.addbeh.2018.07.019
pii:
doi:

Substances chimiques

Nicotinic Agonists 0
Nicotine 6M3C89ZY6R
Cotinine K5161X06LL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-105

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

K Soar (K)

University of East London, United Kingdom.

C Kimber (C)

University of East London, United Kingdom; London South Bank University, United Kingdom.

H McRobbie (H)

Queen Mary University of London, United Kingdom.

L E Dawkins (LE)

London South Bank University, United Kingdom. Electronic address: dawkinl3@lsbu.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrrolidines › Pyrrolidones › Cotinine › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Dispositifs pour fumer › Dispositifs électroniques d'administration de nicotine › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Nicotine › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents cholinergiques › Agonistes cholinergiques › Agonistes nicotiniques › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Liquides et sécrétions biologiques › Sécrétions corporelles › Salive › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Personnes › Fumeurs › Nicotine absorption from e-cigarettes over 12 months.
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Fumer › Vapotage › Nicotine absorption from e-cigarettes over 12 months.